Last reviewed · How we verify
NCT03166891
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Phase 1, PHASE2 trial testing Chiauranib in Ovarian Cancer in 25 participants. Completed in 20 March 2019.
20 March 2019
Quick facts
| Lead sponsor | Chipscreen Biosciences, Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 15 December 2017 |
| Primary completion | 20 March 2019 |
| Estimated completion | 20 March 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chiauranib — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Chipscreen Biosciences, Ltd. — full company profile →
Who can join
Adults 18 to 70, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib(50mg，QD，PO) works in treating patients with relapsed or refractory ovarian cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840 -
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8 -
Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
Yang Y, Yang Y, Yang J, Zhao X, et al · · 2020 · cited 168× · PMID 32850861 · DOI 10.3389/fcell.2020.00758 -
Role of tumor microenvironment in ovarian cancer pathobiology.
Ghoneum A, Afify H, Salih Z, Kelly M, et al · · 2018 · cited 58× · PMID 29854318 · DOI 10.18632/oncotarget.25126 -
Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities.
Ghoneum A, Afify H, Salih Z, Kelly M, et al · · 2018 · cited 46× · PMID 30133163 · DOI 10.1002/cam4.1741 -
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010 -
Aurora B Inhibitors as Cancer Therapeutics.
Kovacs AH, Zhao D, Hou J. · · 2023 · cited 32× · PMID 37110619 · DOI 10.3390/molecules28083385 -
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
Sun Y, Yang L, Hao X, Liu Y, et al · · 2019 · cited 29× · PMID 30642372 · DOI 10.1186/s13045-018-0695-0
Verify or expand the search:
- PubMed search for NCT03166891
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chiauranib
Trials testing the same drug.
- NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
- NCT06492915 — Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma · Phase 2 · active not recruiting
- NCT05497843 — Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) · Phase 2 · completed
- NCT05371899 — Mass Balance Study of [14C]Chiauranib · NA · completed
- NCT05346601 — Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Chipscreen Biosciences, Ltd. trials
Trials by the same sponsor.
- NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
- NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
- NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03166891 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
- Last refreshed: 18 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03166891.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing